Credit: Roswell Park Cancer Institute (RPCI)
Tables showing efficacy of FL118; see
Xiang Ling, Fengzhi Li: An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). Am J Transl Res 2013;5(2):139-154.